India-based Dr Reddy's Laboratories has received a favourable decision from the US Court of Appeals for the Federal Circuit, which concluded that Indivior had not shown that it was likely to succeed on the merits of its infringement case regarding US Patent No 9,931,305, it was reported yesterday.
This decision vacates the District Court's preliminary injunction that had prohibited the company from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. As a result of the ruling, the company will resume its launch activities as soon as permitted.
Following US FDA approval in June, Dr Reddy's began commercialisation of Buprenorphine and Naloxone Sublingual Film, in four strengths including 2mg/0.5mg, 4mg/1mg, 8mg/2mg, and 12mg/3mg, for sale in the US market. Sales and commercialisation activities were subsequently halted as a result of a court-imposed temporary restraining order (TRO) against Dr Reddy's.
Dr Reddy's spokesperson said, 'We are pleased with the decision of the appellate court in Dr Reddy's favour, vacating the preliminary injunction that had prevented Dr Reddy's from bringing this important drug to the public. We are committed to providing affordable and innovative medicines that address the unmet and under-met needs of patients around the world and in particular look forward to taking the lead in helping to fight Opioid Use Disorder.'
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US